Imatinib (Imatinib mesylate [Gleevec]; Novartis Pharma, Basel, Switzerland) is a new molecularly targeted tyrosine kinase receptor blocker that targets tumor cells specifically, limits their growth, induces apoptosis, and leads to a dramatic treatment response and markedly improved long-term survival of patients with GISTs.10 This evidence concerns the gene NTRK1 and neoplasm.